Dicerna announces dosing of first patient in phase 1 clinical trial of DCR-HBVS
Dicerna announced dosing of the first patient in its Phase 1 clinical trial of DCR-HBVS, the Company’s investigational GalXCTM-based therapy for treatment of chronic hepatitis B virus infection in adults. The Company anticipates human proof-of-concept data from the trial in the 2019 fourth quarter. May 16, 2019